Watson Pharma Inc. To Underwrite Clinical Practice Guidelines

New York, NY (January 23, 2001) - Watson Pharma Inc., formerly Schein Pharmaceutical, has agreed to underwrite another edition of the National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) Clinical Practice Guidelines for Treatment of Anemia of Chronic Renal Failure Quick Reference Guide. The reference guide represents a strategy for applying statements and recommendations from the NKF-DOQI initiative. This initiative was launched in 1995 with the goal of improving patient outcomes.

The purpose of the guide is to provide information about the 28 NKF-DOQI Clinical Guidelines for the Treatment of Anemia of Chronic Renal Failure. The majority of patients with chronic renal failure (CRF) develop normocytic normochromic anemia. In most cases, this is caused by deficient production of erythropoietin by the diseased kidneys. Effective treatment of this anemia is important because it improves survival, decreases morbidity and increases the quality of life of these patients. Anemia, when untreated, can cause the following:

  • decreased tissue oxygen delivery and utilization
  • increased cardiac output
  • cardiac enlargement
  • ventricular hypertrophy
  • angina
  • congestive heart failure
  • decreased cognition and mental acuity
  • impaired immune responsiveness

National Kidney Foundation's Materials Department at 1-800-622-9010, extension 175.